Abstract
Background: The role of neoadjuvant chemotherapy (NAC) versus neoadjuvant chemoradiation (NACR) on both downstaging and overall survival has been controversial. The final goal in the treatment of pancreas cancer is downstaging and improvement of overall survival (OS). The newly added variables in the national cancer database (NCDB) in 2018 “post therapy path” provide a unique opportunity to evaluate the role of perioperative treatment on pathologic response and translation of downstaging on OS in a national cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
